Jatenzo Cancer Risk Signal Review: What the Evidence Actually Shows

What Cancer Risks Does Jatenzo Carry According to Its FDA Label?

The Jatenzo prescribing information lists known or suspected androgen-sensitive prostate cancer and male breast cancer as absolute contraindications, consistent with all testosterone formulations. The boxed warning, however, addresses hypertension, not malignancy. This distinction matters clinically because it tells us where the FDA's highest-confidence safety signal sits.

The full prescribing information, available through the FDA's Drugs@FDA database, specifies that testosterone can stimulate the growth of existing androgen-dependent tumors but does not identify Jatenzo as an independent carcinogen in the regulatory sense. [1]

What the Contraindication Language Means in Practice

A contraindication against "known or suspected" prostate cancer means Jatenzo should not be started in any man whose PSA trajectory, digital rectal exam, or biopsy results suggest active disease. Men on active surveillance for low-grade (Gleason 6) prostate cancer fall into a clinical gray zone that requires shared decision-making with urology, not a blanket prescribing rule.

Breast Cancer in Men

Male breast cancer accounts for roughly 1% of all breast cancers in the United States, with approximately 2,800 new cases diagnosed per year according to the American Cancer Society. The testosterone-to-estradiol aromatization pathway is mechanistically plausible as a promoter of hormone-receptor-positive male breast cancer. No Jatenzo-specific breast cancer signal has emerged from the key trial data, but men with existing gynecomastia or breast pathology warrant imaging before initiation. [2]

What Did the Key Jatenzo Trial Actually Measure on Cancer Endpoints?

The primary key study supporting Jatenzo's approval, published by Swerdloff et al. In the Journal of Clinical Endocrinology and Metabolism in 2020 (N=166 hypogonadal men), was designed to demonstrate testosterone normalization, not oncologic safety. [3] The study achieved its primary endpoint: 87% of participants reached a serum total testosterone within the normal reference range (300 to 1,050 ng/dL) at 90 days.

Cancer-specific adverse events were not a prespecified endpoint in Swerdloff et al. The observation period was 120 days, far too short to detect incident malignancies. This limitation is not unique to Jatenzo. Nearly all TRT registration trials are powered for pharmacokinetic endpoints and run for months, not years.

PSA Changes in the Swerdloff Trial

PSA changes were tracked as a safety variable. Mean PSA rose modestly across the treatment period, which is expected when testosterone rises from subnormal to normal physiologic levels. No participant developed PSA values that triggered biopsy-confirmed prostate cancer during the 120-day window. A rise from a suppressed baseline should not be conflated with de novo carcinogenesis. [3]

Hematocrit as an Indirect Safety Signal

Polycythemia (hematocrit above 54%) appeared in a subset of participants. Elevated hematocrit does not cause cancer, but it is associated with thromboembolic events, and venous thromboembolism carries its own morbidity profile. The Jatenzo label recommends checking hematocrit at baseline, at 3 months, and periodically thereafter. [1]

The Broader Testosterone-Prostate Cancer Question

The relationship between exogenous testosterone and prostate cancer has been debated since Charles Huggins' 1941 Nobel Prize-winning work showed castration could regress prostate cancer. For decades, the field operated under a simple linear model: more testosterone equals more prostate cancer risk. That model has since been complicated substantially.

The Saturation Model

Abraham Morgentaler proposed the saturation model in a 2006 paper in the European Urology journal, arguing that androgen receptors in prostate tissue become saturated at relatively low testosterone concentrations (roughly 150 to 200 ng/dL in most studies), after which additional testosterone does not stimulate further growth. [4] This model helps explain why population-level data do not show a consistent correlation between endogenous testosterone levels and prostate cancer incidence.

A 2008 meta-analysis published in the Journal of the National Cancer Institute (Roddam et al., N=3,886 prostate cancer cases across 18 prospective studies) found no significant association between pre-diagnostic serum testosterone and prostate cancer risk (relative risk 0.97 per standard deviation increase, 95% CI 0.91 to 1.04). [5]

What Does Low Testosterone Signal?

Low testosterone may actually correlate with more aggressive prostate cancer at diagnosis. A 2014 analysis in the Journal of Clinical Oncology found that men with lower preoperative testosterone had significantly higher Gleason scores and more advanced pathologic stage at radical prostatectomy. [6] This inverse relationship does not prove causation, but it undermines the simple narrative that higher testosterone always drives worse prostate outcomes.

TRT in Prostate Cancer Survivors: Emerging Data

Prescribing TRT to men previously treated for prostate cancer remains controversial. A 2019 systematic review in European Urology (Kaplan et al.) found no statistically significant increase in biochemical recurrence among carefully selected hypogonadal prostate cancer survivors on TRT, though study sizes were small and follow-up was heterogeneous. [7] The Endocrine Society's 2018 guideline states that testosterone therapy should not be offered to men with "locally advanced or metastatic prostate cancer" but does not universally prohibit use in all prostate cancer survivors. [8]

Oral Testosterone Undecanoate Versus Other TRT Formulations: Does the Route Matter for Cancer Risk?

No head-to-head randomized trial has compared cancer incidence between Jatenzo and injectable or transdermal testosterone. The question of whether oral delivery changes the cancer risk profile relative to other formulations is unanswered by current data.

Pharmacokinetic Differences and Potential Relevance

Jatenzo is absorbed via intestinal lymphatics, bypassing first-pass hepatic metabolism. Peak testosterone (Cmax) after oral dosing tends to show wider intra-subject variability than IM injections of testosterone cypionate 200 mg every two weeks. [1] Whether transient supraphysiologic peaks on any formulation carry greater oncologic risk than steady-state delivery is speculative at this point.

Older Oral Androgens Versus Jatenzo

17-alpha-alkylated oral androgens such as methyltestosterone carry documented hepatotoxicity and have been associated with hepatocellular carcinoma and peliosis hepatis in case reports and case series. Jatenzo is not 17-alpha-alkylated and does not share that hepatic risk profile. The FDA label for Jatenzo does not include a hepatotoxicity warning. Conflating older oral androgen data with Jatenzo would be an error in clinical reasoning. [1]

Post-Marketing Surveillance and Real-World Cancer Signal Data

The FDA Adverse Event Reporting System (FAERS) receives spontaneous case reports after drug approval. FAERS data for oral testosterone undecanoate include sporadic cancer-related reports, as would be expected for any medication used in an older male population where baseline cancer incidence is already elevated.

Interpreting FAERS data requires caution. Reports are not verified, causality is not established, and the denominator (total exposures) is unknown, making incidence rate calculations impossible from FAERS alone. A reported event is not a caused event.

The Testosterone Trials (TTrials) as Contextual Evidence

The TTrials, a coordinated set of seven double-blind placebo-controlled trials (N=790 men 65 years or older with low testosterone), represent the most rigorous short-term RCT safety dataset for TRT in older men. Published across NEJM and JAMA between 2016 and 2018, TTrials used transdermal testosterone gel, not oral TU, but the safety findings remain relevant context. [9]

Prostate cancer was diagnosed in 8 men in the testosterone group and 7 in the placebo group over 12 months, a non-significant difference. High-grade prostate intraepithelial neoplasia (HGPIN) was also similar between groups. The authors noted that a 12-month trial is insufficient to detect treatment-emergent prostate malignancy. [9]

Cardiovascular Signal Versus Cancer Signal

The TTrials showed a higher rate of coronary artery non-calcified plaque volume in the testosterone group (mean increase 41 mm3 vs. 3 mm3 in placebo, P<0.001 by coronary CT angiography). This cardiovascular finding, not a cancer finding, generated more regulatory concern than any oncologic signal from TRT trials. The Jatenzo boxed warning about blood pressure reflects that prioritization.

PSA Monitoring Protocol When Prescribing Jatenzo

Consistent PSA surveillance is the cornerstone of prostate cancer risk management in men on TRT. The Endocrine Society 2018 Clinical Practice Guideline recommends evaluating PSA and performing a digital rectal exam at 3 to 6 months after starting testosterone, and then following the American Cancer Society or American Urological Association age-appropriate screening intervals thereafter. [8]

A practical monitoring framework for Jatenzo:

• Baseline (before first dose): PSA, digital rectal exam (if age 40 or older), hematocrit, lipid panel, blood pressure
• Month 3: Repeat PSA, hematocrit, trough testosterone, blood pressure
• Month 6: Repeat PSA if month-3 showed any rise above 0.75 ng/mL from baseline
• Annually: PSA, hematocrit, lipid panel per standard-of-care intervals
• Trigger for urology referral: PSA velocity above 1.0 ng/mL per year or any single PSA above 4.0 ng/mL (lower threshold, 3.0 ng/mL, in high-risk men or African American men)

A PSA rise of more than 1.4 ng/mL in the first six months on TRT is a frequently cited threshold for urology referral, drawn from expert opinion within the Endocrine Society guidance, though no randomized trial has validated this exact cutoff as a cancer-detection trigger. [8]

Who Should Not Start Jatenzo Due to Cancer-Related Considerations?

Absolute contraindications, per the Jatenzo prescribing information, include:

1. Known or suspected androgen-sensitive prostate cancer
2. Known or suspected male breast cancer

Relative contraindications or situations requiring specialist co-management:

• PSA above 4.0 ng/mL without prior urology evaluation
• Men on active surveillance for low-grade prostate cancer (Gleason grade group 1)
• Prior treatment for prostate cancer (radiation, prostatectomy) without confirmed long-term remission and urology clearance
• First-degree family history of prostate cancer before age 55 (prompts earlier and more frequent PSA monitoring, not automatic exclusion)

Men with a prior history of treated breast cancer, even hormone-receptor-negative disease, warrant oncology consultation before TRT initiation.

Age and Baseline Risk Stratification

Prostate cancer incidence rises sharply with age: approximately 1 in 8 American men will be diagnosed in their lifetime, per the American Cancer Society. [10] Men starting Jatenzo at age 60 or older carry a meaningfully higher baseline prostate cancer risk than men in their 30s with primary hypogonadism. This baseline risk should be communicated explicitly during informed consent. The drug does not appear to accelerate existing subclinical disease beyond what endogenous testosterone would do at normal levels, based on current evidence, but the evidence base for this claim rests on trials powered for PK endpoints, not oncologic ones.

What the Endocrine Society Guidelines Say About TRT and Cancer

The 2018 Endocrine Society Clinical Practice Guideline on testosterone therapy in men states: "We recommend against starting testosterone therapy in patients with prostate cancer" in the active treatment or surveillance phases and advises that the decision in men with a history of treated prostate cancer "requires a careful discussion of the known and unknown risks and benefits." [8]

The guideline also acknowledges the absence of randomized trial data directly linking TRT to prostate cancer incidence. The recommendation against use in active disease is based on the well-established androgen-dependence of most prostate cancer cells, not on RCT evidence that TRT causes de novo cancer. This distinction is important for patient counseling: the concern is promotion of existing disease, not initiation of new malignancy.

Current Knowledge Gaps and What Ongoing Research May Reveal

The fundamental limitation of all current data is duration. No published randomized trial of any testosterone formulation has followed men for the 10 to 15 years needed to detect a meaningful change in prostate cancer incidence, given the disease's typical latency. The planned long-term follow-up of the TRAVERSE trial (N=5,204 men with hypogonadism and elevated cardiovascular risk, primary cardiovascular endpoint) may yield the most strong long-term safety dataset for any TRT formulation to date. TRAVERSE primary cardiovascular results were published in NEJM in 2023, showing non-inferiority to placebo for major adverse cardiovascular events; cancer endpoint data from extended follow-up remain pending. [11]

Until longer-duration RCT data are available, prescribing decisions should incorporate individual baseline cancer risk, PSA trajectory, patient age, and the severity of hypogonadal symptoms. The absence of a proven cancer signal is not the same as proven cancer safety.

Men with confirmed hypogonadism (two morning total testosterone values below 300 ng/dL, per Endocrine Society thresholds) who are appropriately screened and monitored can be prescribed Jatenzo with a risk profile that current evidence suggests is acceptable, provided the contraindications above are respected and PSA monitoring is maintained at the intervals outlined by Endocrine Society guidance. [8]